SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

ifetroban

CPIX·Cumberland Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 2
Time to market
At least 3-5 years if successful, Phase 3 trials have not yet started for any indication.
Why 5/10
Ifetroban is mid-stage (Phase 2) across all indications with no hard-dated binary catalyst in the next ~12 months. The next major event, an FDA Type B meeting to design a Phase 3 trial for DMD cardiomyopathy, has been announced as a goal but not yet scheduled. The asset-sale transformation (completed June 2026) was the recent major catalyst; the stock has already re-rated from ~$3.75 to ~$6.00. Impact is moderate (5) because ifetroban is now the company's sole asset, but no dated binary is imminent.
Actionable Insight NEUTRAL

Cumberland is now a pure-play ifetroban development company with ~$100M+ cash post the Apotex sale. The key swing factor is when and how management engages the FDA on a Phase 3 pathway for DMD cardiomyopathy, watch for an FDA meeting announcement or a specific Phase 3 timeline. The stock remains highly speculative with thin liquidity and a mixed analyst consensus (3 Hold, 1 Sell, 2 Strong Sell).

Price Chart

Loading chart...

Executive Summary

Ifetroban is an oral drug originally discovered by Bristol-Myers Squibb, now owned and developed by Cumberland Pharmaceuticals (CPIX). It targets the thromboxane receptor to fight inflammation and fibrosis in rare diseases. In February 2025, positive Phase 2 data showed it improved heart function in Duchenne muscular dystrophy (DMD) patients, the leading cause of death in DMD. The drug has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations for DMD cardiomyopathy. Cumberland recently sold its entire commercial product portfolio to Apotex for $100M (closed June 2026) and is now a pure-play development-stage biotech focused entirely on ifetroban across DMD, systemic sclerosis, and idiopathic pulmonary fibrosis. With no PDUFA date set and Phase 3 not yet begun, the stock trades on pipeline narrative and regulatory-pathway catalysts rather than near-term approval.

How It Works

Ifetroban blocks a specific receptor (the thromboxane receptor) on cells that, when overactivated, drives inflammation, tissue scarring (fibrosis), and blood vessel constriction. By blocking this receptor, the drug aims to prevent or slow damage to the heart and lungs in rare diseases where these processes are out of control.

Trial Status

Positive Phase 2 top-line results announced Feb 2025 for DMD cardiomyopathy (FIGHT DMD trial). Phase 2 trials are also recruiting in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF, FIGHTING FIBROSIS trial). The DMD program has an ongoing open-label extension. Management plans to discuss a pivotal trial path with the FDA for DMD.

The Two-Sided Case

▲ Bull Case5
Ifetroban would be the first therapy specifically indicated for DMD-related heart disease, the leading cause of death in DMD patients, a clear, unmet-need market (source: Pharmacytimes.com, Medthority.com)
Phase 2 FIGHT DMD data showed high-dose ifetroban improved LVEF by 3.3% overall and 5.4% vs control at 12 months, the first successful Phase 2 targeting DMD cardiac complications (source: Clinicaltrialsarena.com, Clival.com)
FDA granted Fast Track (Feb 2026), Orphan Drug, and Rare Pediatric Disease designations, offering expedited review, tax credits, and potential priority review voucher (source: Drugs.com, Rarediseaseadvisor.com)
Company completed $100M asset sale to Apotex in June 2026, leaving it debt-free with ~$110M pro forma cash to fund ifetroban development exclusively (source: Tipranks.com, SEC DEFM14A filing)
Preclinical data shows ifetroban prevents and resolves lung fibrosis in multiple models, providing a mechanistic rationale for the IPF and SSc programs (source: BioSpace, Mount Sinai clinical trial page)
▼ Bear Case6
Cumberland is now a single-asset development-stage company with no commercial revenue, any setback in ifetroban's development would be company-threatening (source: SEC DEFM14A filing)
Phase 2 FIGHT DMD data came from only 41 patients; the 3.3% LVEF improvement, while positive, is modest and may not translate to a statistically significant Phase 3 result (source: Clival.com, Neurologylive.com)
No Phase 3 trial has been designed or initiated for any indication, approval is likely 3-5 years away at minimum, with significant dilution risk (CPIX dilution reported as 390%) (source: Fintel.io, MarketBeat)
Analyst consensus is bearish-mixed: 0 Buy, 3 Hold, 1 Sell, 2 Strong Sell, no analyst sees a compelling risk/reward at current levels
Ifetroban was originally a BMS cardiovascular drug that never reached approval, its repurposing carries clinical and regulatory risk (source: drugs.ncats.io)
Short interest of ~242K shares (1.62% of outstanding as of June 30, 2026) with 5.09 days to cover indicates bearish positioning by sophisticated shorts

Upcoming Catalysts

  • FDA Type B meeting to discuss Phase 3 pivotal trial design for DMD cardiomyopathy (management stated goal, no specific date yet)
  • Phase 2 FIGHTING FIBROSIS trial for IPF, topline readout (recruiting; no estimated primary completion date published)
  • Phase 2 systemic sclerosis trial, interim or final data (ongoing; NCT02682511)
  • Open-label extension data updates from FIGHT DMD trial, could be presented at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Cumberland Pharmaceuticals Inc. Press Release CPIX ·Originating report

Sources · 15

Hover a chip for the title
1 adisinsight.springer.com2 cumberlandpharma.com3 pharmacytimes.com4 fiercebiotech.com5 medthority.com6 touchcardio.com7 clinicaltrialsarena.com8 tipranks.com9 biopharmawatch.com10 rarediseaseadvisor.com11 drugs.com12 neurologylive.com13 clival.com14 sec.gov15 drugs.ncats.io